Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
*Sandimmune is a registered trademark
Sandostatin* / Sandostatin* LAR*
(octreotide acetate injection) / (octreotide as acetate for injectable suspension)
Synthetic Octapeptide Analogue of Somatostatin
*Sandostatin and LAR are registered trademarks
*Sebivo is a registered trademark
Long-acting muscarinic antagonist
*Seebri and Breezhaler are registered trademarks
*Simulect is a registered trademark
*Slow-K is a registered trademark
(levodopa, carbidopa and entacapone)
Anti-parkinsonian Dopaminergic Agent
*Stalevo is a registered trademark
Oral Antidiabetic Agent
*Starlix is a registered trademark
(cosyntropin zinc hydroxide)
*Synacthen is a registered trademark
Novartis is one of the industry’s biggest investors in research.
This information is intended for Canadian healthcare professionals only
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.